Vor Biopharma reported total assets of $481.05M and total liabilities of $681.25M for the quarter ended Jun 2026, up 134.2% year over year. This balance sheet covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 1.76M | 2.08M | 2.51M | 3.08M | 3.98M | 4.61M | 5.45M | 6.31M | 7.20M | 8.09M | 9.03M | 9.90M | 10.75M | 11.21M | 12.03M | 0.00M | 0.03M | 0.05M | 0.09M | |||||||
| Assets | ||||||||||||||||||||||||||
| Current Assets | ||||||||||||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 143.03M | 119.80M | 90.04M | 62.95M | 60.83M | 57.71M | 42.45M | 32.21M | 45.03M | 31.36M | 44.96M | 76.08M | 52.80M | 81.95M | 50.05M | 190.57M | 160.46M | 396.49M | 169.87M | 107.86M | ||||||
| Prepaid Assets | 5.36M | 4.84M | 6.47M | 5.47M | 4.89M | 4.37M | 6.24M | 3.95M | 3.67M | 3.15M | 3.83M | 4.05M | 4.20M | 4.20M | 4.51M | 1.50M | 1.28M | 1.75M | 6.39M | 5.88M | ||||||
| Current Assets | 232.07M | 214.40M | 190.30M | 158.84M | 142.73M | 236.95M | 216.90M | 191.39M | 164.44M | 140.80M | 111.82M | 90.26M | 67.30M | 96.51M | 64.85M | 204.93M | 172.49M | 458.11M | 500.78M | 475.11M | ||||||
| Non-Current Assets | ||||||||||||||||||||||||||
| Property, Plant & Equipment (Net) | 5.99M | 6.85M | 11.77M | 14.83M | 12.96M | 12.63M | 11.86M | 11.46M | 10.82M | 10.05M | 9.16M | 8.29M | 7.47M | 6.58M | 5.99M | 0.27M | 0.53M | 0.56M | 0.65M | |||||||
| Other Non-Current Assets | 2.41M | 3.25M | 2.41M | 2.41M | 2.41M | 2.92M | 2.41M | 2.41M | 2.41M | 4.81M | 2.41M | 3.06M | 2.51M | 2.41M | 2.41M | 0.42M | 0.27M | 2.38M | 2.41M | 2.41M | ||||||
| Non-Current Assets | 26.56M | 28.19M | 43.97M | 65.77M | 63.64M | 62.42M | 60.63M | 59.59M | 58.59M | 57.32M | 55.21M | 51.33M | 48.70M | 46.38M | 44.47M | 0.44M | 3.75M | 6.02M | 5.97M | 5.95M | ||||||
| Assets | 258.63M | 242.59M | 234.27M | 224.62M | 206.37M | 299.37M | 277.53M | 250.99M | 223.02M | 198.13M | 167.03M | 141.59M | 115.99M | 142.89M | 109.31M | 205.37M | 176.24M | 464.13M | 506.75M | 481.05M | ||||||
| Liabilities | ||||||||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||||||||
| Accounts Payables | 1.96M | 1.54M | 1.25M | 1.27M | 0.82M | 1.77M | 3.22M | 1.65M | 1.31M | 0.81M | 2.33M | 2.01M | 1.32M | 1.50M | 3.73M | 0.67M | 0.89M | 5.13M | 1.04M | 4.00M | ||||||
| Payables | 1.96M | 1.54M | 1.25M | 1.27M | 0.82M | 1.77M | 3.22M | 1.65M | 1.31M | 0.81M | 2.33M | 2.01M | 1.32M | 1.50M | 3.73M | 0.67M | 0.89M | 5.13M | 1.04M | 4.00M | ||||||
| Accumulated Expenses | 5.68M | 6.33M | 9.26M | 6.29M | 6.29M | 7.89M | 5.49M | 7.26M | 10.27M | 10.88M | 6.80M | 7.66M | 8.85M | 12.89M | 8.69M | 58.10M | 17.70M | 19.76M | 14.73M | 20.48M | ||||||
| Other Accumulated Expenses | 0.80M | 0.80M | 2.95M | 2.01M | 1.50M | 0.57M | 0.63M | 0.47M | 2.35M | 1.06M | 0.59M | 0.67M | 0.31M | 0.87M | 0.66M | 0.14M | 0.19M | 0.55M | 0.70M | 0.32M | ||||||
| Current Leases | 1.15M | 1.84M | 7.28M | 4.43M | 3.76M | 3.27M | 3.71M | 3.69M | 3.74M | 3.83M | 3.96M | 4.11M | 4.16M | 4.21M | 4.27M | 0.25M | 0.28M | 0.31M | 0.34M | |||||||
| Total Current Liabilities | 9.21M | 10.15M | 18.14M | 12.26M | 11.10M | 13.12M | 12.58M | 12.72M | 15.39M | 15.57M | 13.21M | 13.80M | 14.35M | 18.61M | 16.73M | 58.77M | 18.84M | 25.17M | 16.08M | 24.81M | ||||||
| Non-Current Liabilities | ||||||||||||||||||||||||||
| Preferred Stock Liabilities | ||||||||||||||||||||||||||
| Operating Leases | 16.46M | 16.17M | 21.68M | 37.38M | 36.54M | 35.64M | 34.74M | 33.82M | 32.85M | 31.83M | 30.78M | 29.71M | 28.69M | 27.61M | 26.52M | 2.81M | 2.72M | 2.63M | 2.54M | |||||||
| Other Non-Current Liabilities | 1,652.30M | 2,380.08M | 600.55M | 638.46M | 653.89M | |||||||||||||||||||||
| Total Non-Current Liabilities | 46.23M | 58.77M | 21.65M | 27.89M | 18.71M | 27.36M | ||||||||||||||||||||
| Total Liabilities | 25.68M | 26.33M | 39.82M | 49.64M | 47.64M | 48.76M | 47.32M | 46.54M | 48.24M | 47.40M | 43.99M | 43.51M | 43.04M | 46.23M | 43.24M | 1,711.07M | 2,401.72M | 628.44M | 657.17M | 681.25M | ||||||
| Shareholder's Equity | ||||||||||||||||||||||||||
| Common Equity | 232.96M | 216.26M | 194.45M | 174.97M | 158.73M | 250.61M | 230.22M | 204.45M | 174.78M | 150.72M | 123.03M | 98.08M | 72.95M | 96.66M | 66.07M | -1505.70M | -2225.49M | -164.31M | -150.42M | -200.20M | ||||||
| Liabilities and Shareholders Equity | 258.63M | 242.59M | 234.27M | 224.62M | 206.37M | 299.37M | 277.53M | 250.99M | 223.02M | 198.13M | 167.03M | 141.59M | 115.99M | 142.89M | 109.31M | 205.37M | 176.24M | 464.13M | 506.75M | 481.05M | ||||||
| Retained Earnings | -111.87M | -130.12M | -152.86M | -174.52M | -198.31M | -222.22M | -250.65M | -280.63M | -313.82M | -340.08M | -370.88M | -398.72M | -426.30M | -456.99M | -489.50M | -2063.15M | -2875.83M | -1152.97M | -1372.60M | -1435.40M | ||||||
| Treasury Shares |